754 related articles for article (PubMed ID: 15301874)
41. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.
Cullen MH; Billingham LJ; Woodroffe CM; Chetiyawardana AD; Gower NH; Joshi R; Ferry DR; Rudd RM; Spiro SG; Cook JE; Trask C; Bessell E; Connolly CK; Tobias J; Souhami RL
J Clin Oncol; 1999 Oct; 17(10):3188-94. PubMed ID: 10506617
[TBL] [Abstract][Full Text] [Related]
42. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.
Blanke C; DeVore R; Shyr Y; Epstein B; Murray M; Hande K; Stewart S; Johnson D
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):111-6. PubMed ID: 9054884
[TBL] [Abstract][Full Text] [Related]
43. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
[TBL] [Abstract][Full Text] [Related]
44. Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
Lee CB; Stinchcombe TE; Moore DT; Morris DE; Hayes DN; Halle J; Rosenman JG; Rivera MP; Socinski MA
J Thorac Oncol; 2009 Jan; 4(1):74-9. PubMed ID: 19096310
[TBL] [Abstract][Full Text] [Related]
45. Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.
Tan EH; Wee J; Ang PT; Fong KW; Leong SS; Khoo KS; Tan T; Lee KS; Eng P; Hsu A; Tan YK; Chua EJ; Ong YY
Acta Oncol; 1999; 38(8):1005-9. PubMed ID: 10665753
[TBL] [Abstract][Full Text] [Related]
46. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
Di Maio M; Krzakowski M; Fougeray R; Kowalski DM; Gridelli C
Lung Cancer; 2012 Jul; 77(1):116-20. PubMed ID: 22361218
[TBL] [Abstract][Full Text] [Related]
47. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
[TBL] [Abstract][Full Text] [Related]
49. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
50. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer.
Crinò L; Latini P; Meacci M; Corgna E; Maranzano E; Darwish S; Minotti V; Santucci A; Tonato M
Ann Oncol; 1993 Dec; 4(10):847-51. PubMed ID: 8117604
[TBL] [Abstract][Full Text] [Related]
51. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Williams CD; Gajra A; Ganti AK; Kelley MJ
Cancer; 2014 Jul; 120(13):1939-47. PubMed ID: 24668613
[TBL] [Abstract][Full Text] [Related]
52. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
[TBL] [Abstract][Full Text] [Related]
53. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer.
Lau DH; Crowley JJ; Gandara DR; Hazuka MB; Albain KS; Leigh B; Fletcher WS; Lanier KS; Keiser WL; Livingston RB
J Clin Oncol; 1998 Sep; 16(9):3078-81. PubMed ID: 9738578
[TBL] [Abstract][Full Text] [Related]
54. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.
Paesmans M; Sculier JP; Libert P; Bureau G; Dabouis G; Thiriaux J; Michel J; Van Cutsem O; Sergysels R; Mommen P; Klastersky J
Eur J Cancer; 1997 Dec; 33(14):2326-32. PubMed ID: 9616276
[TBL] [Abstract][Full Text] [Related]
55. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
[TBL] [Abstract][Full Text] [Related]
56. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.
Depierre A; Milleron B; Moro-Sibilot D; Chevret S; Quoix E; Lebeau B; Braun D; Breton JL; Lemarié E; Gouva S; Paillot N; Bréchot JM; Janicot H; Lebas FX; Terrioux P; Clavier J; Foucher P; Monchâtre M; Coëtmeur D; Level MC; Leclerc P; Blanchon F; Rodier JM; Thiberville L; Villeneuve A; Westeel V; Chastang C;
J Clin Oncol; 2002 Jan; 20(1):247-53. PubMed ID: 11773176
[TBL] [Abstract][Full Text] [Related]
57. An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC.
Berghmans T; Lafitte JJ; Scherpereel A; Paesmans M; Lecomte J; Marco VG; Meert AP; Leclercq N; Sculier JP;
Anticancer Res; 2013 Dec; 33(12):5477-82. PubMed ID: 24324084
[TBL] [Abstract][Full Text] [Related]
58. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
Chhajed PN; Baty F; Pless M; Somandin S; Tamm M; Brutsche MH
Chest; 2006 Dec; 130(6):1803-7. PubMed ID: 17167000
[TBL] [Abstract][Full Text] [Related]
59. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer.
Harris JP; Murphy JD; Hanlon AL; Le QT; Loo BW; Diehn M
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):872-84. PubMed ID: 24495591
[TBL] [Abstract][Full Text] [Related]
60. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.
Clamon G; Herndon J; Cooper R; Chang AY; Rosenman J; Green MR
J Clin Oncol; 1999 Jan; 17(1):4-11. PubMed ID: 10458211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
